HEADER IMMUNE SYSTEM/RECEPTOR 31-MAR-05 2BNQ TITLE STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL TITLE 2 VACCINES COMPND MOL_ID: 1; COMPND 2 MOLECULE: HLA CLASS I HISTOCOMPATIBILITY ANTIGEN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EXTRACELLULAR ALPHA-1, -2, -3, RESIDUES 25-300; COMPND 5 SYNONYM: MHC, A-2 ALPHA CHAIN PRECURSOR; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: BETA-2-MICROGLOBULIN; COMPND 9 CHAIN: B; COMPND 10 FRAGMENT: BETA-2-MICROGLOBULIN, RESIDUES 21-119; COMPND 11 SYNONYM: HDCMA22P, B2M; COMPND 12 ENGINEERED: YES; COMPND 13 MOL_ID: 3; COMPND 14 MOLECULE: SYNTHETIC PEPTIDE; COMPND 15 CHAIN: C; COMPND 16 ENGINEERED: YES; COMPND 17 MOL_ID: 4; COMPND 18 MOLECULE: T-CELL RECEPTOR ALPHA CHAIN V REGION; COMPND 19 CHAIN: D; COMPND 20 ENGINEERED: YES; COMPND 21 OTHER_DETAILS: CONTAINS ALSO C (CONSTANT) REGION; COMPND 22 MOL_ID: 5; COMPND 23 MOLECULE: T-CELL RECEPTOR BETA CHAIN C REGION; COMPND 24 CHAIN: E; COMPND 25 FRAGMENT: EXTRACELLULAR, RESIDUES 1-130; COMPND 26 SYNONYM: TRBC1; COMPND 27 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 CELL: ANTIGEN PRESENTING CELL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BLR; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PETT22B+; SOURCE 10 OTHER_DETAILS: REFOLDED FROM INCLUSION BODIES; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 13 ORGANISM_COMMON: HUMAN; SOURCE 14 ORGANISM_TAXID: 9606; SOURCE 15 CELL: ANTIGEN PRESENTING CELL; SOURCE 16 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 17 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 18 EXPRESSION_SYSTEM_STRAIN: BLR; SOURCE 19 EXPRESSION_SYSTEM_VECTOR: PETT22B+; SOURCE 20 OTHER_DETAILS: REFOLDED FROM INCLUSION BODIES FROM INCLUSION BODIES; SOURCE 21 MOL_ID: 3; SOURCE 22 SYNTHETIC: YES; SOURCE 23 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 24 ORGANISM_COMMON: HUMAN; SOURCE 25 ORGANISM_TAXID: 9606; SOURCE 26 OTHER_DETAILS: REFOLDED FROM INCLUSION BODIES. PEPTIDE CHAIN C.; SOURCE 27 MOL_ID: 4; SOURCE 28 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 29 ORGANISM_COMMON: HUMAN; SOURCE 30 ORGANISM_TAXID: 9606; SOURCE 31 TISSUE: IMMUNE SYTEM; SOURCE 32 CELL: T-LYMPHOCYTE; SOURCE 33 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 34 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 35 EXPRESSION_SYSTEM_STRAIN: BLR; SOURCE 36 EXPRESSION_SYSTEM_VECTOR: PETT22B+; SOURCE 37 OTHER_DETAILS: REFOLDED FROM INCLUSION BODIES; SOURCE 38 MOL_ID: 5; SOURCE 39 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 40 ORGANISM_COMMON: HUMAN; SOURCE 41 ORGANISM_TAXID: 9606; SOURCE 42 TISSUE: IMMUNE SYTEM; SOURCE 43 CELL: T-LYMPHOCYTE; SOURCE 44 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 45 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 46 EXPRESSION_SYSTEM_STRAIN: BLR; SOURCE 47 EXPRESSION_SYSTEM_VECTOR: PETT22B+; SOURCE 48 OTHER_DETAILS: REFOLDED FROM INCLUSION BODIES. KEYWDS IMMUNE SYSTEM/RECEPTOR, IMMUNE SYSTEM-RECEPTOR-COMPLEX, TCR, MHC, KEYWDS 2 IMMUNODOMINANCE, FLU, COMPLEX, TRANSMEMBRANE, GLYCOPROTEIN, KEYWDS 3 POLYMORPHISM, T-CELL, RECEPTOR, SUPERAGONIST PEPTIDE T-CELL KEYWDS 4 VACCINES, IMMUNE SYSTEM-RECEPTOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.-L.CHEN,G.STEWART-JONES,G.BOSSI,N.M.LISSIN,L.WOOLDRIDGE,E.M.L.CHOI, AUTHOR 2 G.HELD,P.R.DUNBAR,R.M.ESNOUF,M.SAMI,J.M.BOULTIER,P.J.RIZKALLAH, AUTHOR 3 C.RENNER,A.SEWELL,P.A.VAN DER MERWE,B.K.JACKOBSEN,G.GRIFFITHS, AUTHOR 4 E.Y.JONES,V.CERUNDOLO REVDAT 4 13-DEC-23 2BNQ 1 REMARK REVDAT 3 25-NOV-15 2BNQ 1 AUTHOR REMARK VERSN FORMUL REVDAT 2 24-FEB-09 2BNQ 1 VERSN REVDAT 1 23-MAY-05 2BNQ 0 JRNL AUTH J.-L.CHEN,G.STEWART-JONES,G.BOSSI,N.M.LISSIN,L.WOOLDRIDGE, JRNL AUTH 2 E.M.L.CHOI,G.HELD,P.R.DUNBAR,R.M.ESNOUF,M.SAMI,J.M.BOULTIER, JRNL AUTH 3 P.RIZKALLAH,C.RENNER,A.SEWELL,P.A.VAN DER MERWE, JRNL AUTH 4 B.K.JACKOBSEN,G.GRIFFITHS,E.Y.JONES,V.CERUNDOLO JRNL TITL STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY JRNL TITL 2 OF T CELL VACCINES JRNL REF J.EXP.MED. V. 201 1243 2005 JRNL REFN ISSN 0022-1007 JRNL PMID 15837811 JRNL DOI 10.1084/JEM.20042323 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.-L.CHEN,P.R.DUNBAR,U.GILEADI,E.JAGER,S.GNJATIC,Y.NAGATA, REMARK 1 AUTH 2 E.STOCKERT,D.L.PANICALI,Y.-T.CHEN,A.KNUTH,L.J.OLD, REMARK 1 AUTH 3 V.CERUNDOLO REMARK 1 TITL IDENTIFICATION OF NY-ESO-1 PEPTIDE ANALOGUES CAPABLE OF REMARK 1 TITL 2 IMPROVED STIMULATION OF TUMOR-REACTIVE CTL REMARK 1 REF J.IMMUNOL. V. 165 948 2000 REMARK 1 REFN ISSN 0022-1767 REMARK 1 PMID 10878370 REMARK 1 DOI 10.4049/JIMMUNOL.165.2.948 REMARK 2 REMARK 2 RESOLUTION. 1.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.81 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 217685.720 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 84.6 REMARK 3 NUMBER OF REFLECTIONS : 94142 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.226 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 4779 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.004 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.76 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 42.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 4469 REMARK 3 BIN R VALUE (WORKING SET) : 0.3070 REMARK 3 BIN FREE R VALUE : 0.3410 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 237 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.022 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 6626 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 527 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 22.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 32.10 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -5.93000 REMARK 3 B22 (A**2) : 12.31000 REMARK 3 B33 (A**2) : -6.38000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -1.66000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.23 REMARK 3 ESD FROM SIGMAA (A) : 0.19 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.27 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.23 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 25.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.740 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.370 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.140 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.220 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.300 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.36 REMARK 3 BSOL : 43.70 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER.PARAM REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2BNQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 31-MAR-05. REMARK 100 THE DEPOSITION ID IS D_1290023460. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-OCT-02 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.20 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 112638 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.700 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.900 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.3 REMARK 200 DATA REDUNDANCY : 8.000 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.76 REMARK 200 COMPLETENESS FOR SHELL (%) : 58.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.58000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: EPMR REMARK 200 STARTING MODEL: PDB ENTRY 1OGA REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.74 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.72 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.20 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 31.24500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: PENTAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: PENTAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 10700 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 37320 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -61.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLN A 224 CB REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO E 179 C - N - CA ANGL. DEV. = 9.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 29 -128.99 54.34 REMARK 500 HIS A 114 98.07 -165.22 REMARK 500 GLN A 180 54.60 -92.68 REMARK 500 VAL A 194 -86.83 -103.53 REMARK 500 SER A 195 -109.94 -81.85 REMARK 500 PRO A 210 -179.50 -67.13 REMARK 500 ASN B 17 127.54 -38.18 REMARK 500 GLU B 47 -92.44 -53.80 REMARK 500 TRP B 60 -4.65 73.59 REMARK 500 ALA D 86 -179.58 173.68 REMARK 500 ASP D 120 58.47 -147.49 REMARK 500 SER D 131 116.04 -170.67 REMARK 500 SER D 132 12.99 -64.11 REMARK 500 MET D 166 79.10 -113.45 REMARK 500 ILE E 45 -61.55 -93.70 REMARK 500 SER E 86 -174.19 -176.41 REMARK 500 ASN E 97 -140.48 58.46 REMARK 500 PRO E 202 -6.21 -58.59 REMARK 500 TRP E 221 -73.20 -133.39 REMARK 500 THR E 222 72.75 35.35 REMARK 500 GLN E 223 -102.01 -122.06 REMARK 500 ASP E 224 -40.87 -173.94 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2020 DISTANCE = 6.02 ANGSTROMS REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1A1M RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDETYPDINQML FROM REMARK 900 GAG PROTEIN OF HIV2 REMARK 900 RELATED ID: 1A1N RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTYFROM THE REMARK 900 NEF PROTEIN (75- 82) OF HIV1 REMARK 900 RELATED ID: 1A1O RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) REMARK 900 FROM THE MALARIA PARASITE P. FALCIPARUM REMARK 900 RELATED ID: 1A6Z RELATED DB: PDB REMARK 900 HFE (HUMAN) HEMOCHROMATOSIS PROTEIN REMARK 900 RELATED ID: 1A9B RELATED DB: PDB REMARK 900 DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE REMARK 900 TO NONSTANDARD POSITIONING OF THE C-TERMINUS REMARK 900 RELATED ID: 1A9E RELATED DB: PDB REMARK 900 DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE REMARK 900 TO NONSTANDARD POSITIONING OF THE C-TERMINUS REMARK 900 RELATED ID: 1AGB RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGRKKYKL - 3R MUTATION) REMARK 900 RELATED ID: 1AGC RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYQL - 7Q MUTATION) REMARK 900 RELATED ID: 1AGD RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYKL - INDEX PEPTIDE) REMARK 900 RELATED ID: 1AGE RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYRL - 7R MUTATION) REMARK 900 RELATED ID: 1AGF RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKRYKL - 5R MUTATION) REMARK 900 RELATED ID: 1AKJ RELATED DB: PDB REMARK 900 COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 ANDTHE T CELL REMARK 900 CORECEPTOR CD8 REMARK 900 RELATED ID: 1AO7 RELATED DB: PDB REMARK 900 COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA- REMARK 900 A 0201 REMARK 900 RELATED ID: 1B0G RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH REMARK 900 BETA 2- MICROGLOBULIN AND HUMAN PEPTIDE P1049 REMARK 900 RELATED ID: 1B0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A0201 COMPLEXED WITH A PEPTIDE WITH THE REMARK 900 CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP REMARK 900 RELATED ID: 1BD2 RELATED DB: PDB REMARK 900 COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND REMARK 900 MHC CLASS I MOLECULE HLA-A 0201 REMARK 900 RELATED ID: 1CE6 RELATED DB: PDB REMARK 900 MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUSNUCLEOPROTEIN PEPTIDE REMARK 900 RELATED ID: 1DE4 RELATED DB: PDB REMARK 900 HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRINRECEPTOR REMARK 900 RELATED ID: 1DUY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A0201/OCTAMERIC TAX PEPTIDE COMPLEX REMARK 900 RELATED ID: 1DUZ RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) INCOMPLEX REMARK 900 WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN REMARK 900 RELATED ID: 1E27 RELATED DB: PDB REMARK 900 NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV REMARK 900 IMMUNODOMINANT EPITOPE KM1 (LPPVVAKEI) REMARK 900 RELATED ID: 1E28 RELATED DB: PDB REMARK 900 NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV REMARK 900 IMMUNODOMINANT EPITOPE KM2 (TAFTIPSI) REMARK 900 RELATED ID: 1EFX RELATED DB: PDB REMARK 900 STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL REMARK 900 RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3 REMARK 900 RELATED ID: 1EXU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR REMARK 900 RELATED ID: 1GZP RELATED DB: PDB REMARK 900 CD1B IN COMPLEX WITH GM2 GANGLIOSIDE REMARK 900 RELATED ID: 1GZQ RELATED DB: PDB REMARK 900 CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL REMARK 900 RELATED ID: 1HHG RELATED DB: PDB REMARK 900 RELATED ID: 1HHH RELATED DB: PDB REMARK 900 RELATED ID: 1HHI RELATED DB: PDB REMARK 900 RELATED ID: 1HHJ RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEX WITH REMARK 900 A NONAMERIC PEPTIDE FROM HIV-1 REVERSE TRANSCRIPTASE (RESIDUES 309- REMARK 900 317) REMARK 900 RELATED ID: 1HHK RELATED DB: PDB REMARK 900 RELATED ID: 1HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2 ( HLA-A2, HUMAN REMARK 900 LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 1HSA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA- B(ASTERISK)2705 REMARK 900 RELATED ID: 1HSB RELATED DB: PDB REMARK 900 CLASS I HISTOCOMPATIBILITY ANTIGEN AW68.1 ( LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 1I1F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH REMARK 900 BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y REMARK 900 RELATED ID: 1I1Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH REMARK 900 BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y REMARK 900 RELATED ID: 1I4F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4- PEPTIDE COMPLEX REMARK 900 RELATED ID: 1I7R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1058 REMARK 900 RELATED ID: 1I7T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-5V REMARK 900 RELATED ID: 1I7U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-6V REMARK 900 RELATED ID: 1IM3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2BOUND TO REMARK 900 THE MHC CLASS I MOLECULE HLA-A2/TAX REMARK 900 RELATED ID: 1IM9 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELLINHIBITORY REMARK 900 RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4 REMARK 900 RELATED ID: 1JF1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ADECAMERIC ALTERED REMARK 900 PEPTIDE LIGAND FROM THE MART-1/MELAN-A REMARK 900 RELATED ID: 1JGE RELATED DB: PDB REMARK 900 HLA-B*2705 BOUND TO NONA-PEPTIDE M9 REMARK 900 RELATED ID: 1JNJ RELATED DB: PDB REMARK 900 NMR SOLUTION STRUCTURE OF THE HUMAN BETA2- MICROGLOBULIN REMARK 900 RELATED ID: 1JHT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ANONAMERIC ALTERED REMARK 900 PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A. REMARK 900 RELATED ID: 1QLF RELATED DB: PDB REMARK 900 MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G REMARK 900 RELATED ID: 1QQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER REMARK 900 CELL INHIBITORY RECEPTOR REMARK 900 RELATED ID: 1QR1 RELATED DB: PDB REMARK 900 POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A REMARK 900 LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE REMARK 900 RELATED ID: 1QRN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO REMARK 900 ALTERED HTLV-1 TAX PEPTIDE P6A REMARK 900 RELATED ID: 1QSE RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN A6-TCR BOUND TO HLA- A2 COMPLEXED WITH ALTERED REMARK 900 HTLV-1 TAX PEPTIDE V7R REMARK 900 RELATED ID: 1QSF RELATED DB: PDB REMARK 900 STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 REMARK 900 TAX PEPTIDE Y8A REMARK 900 RELATED ID: 1K5N RELATED DB: PDB REMARK 900 HLA-B*2709 BOUND TO NONA-PEPTIDE M9 REMARK 900 RELATED ID: 1KPR RELATED DB: PDB REMARK 900 THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE REMARK 900 HLA-E REMARK 900 RELATED ID: 1KTL RELATED DB: PDB REMARK 900 THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE REMARK 900 HLA-E REMARK 900 RELATED ID: 1LDS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2 -MICROGLOBULIN REMARK 900 RELATED ID: 1OF2 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE REMARK 900 INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VPAC1) PEPTIDE (RESIDUES 400- REMARK 900 408) REMARK 900 RELATED ID: 1FYT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELLRECEPTOR, REMARK 900 INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS IIMOLECULE, HLA-DR1 REMARK 900 RELATED ID: 1KGC RELATED DB: PDB REMARK 900 IMMUNE RECEPTOR REMARK 900 RELATED ID: 1TMC RELATED DB: PDB REMARK 900 TRUNCATED HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA-AW68 REMARK 900 COMPLEXED WITH A DECAMERIC PEPTIDE (EVAPPEYHRK) REMARK 900 RELATED ID: 2CLR RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEXED REMARK 900 WITH A DECAMERIC PEPTIDE FROM CALRETICULIN REMARK 900 RELATED ID: 2HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN AW 68.1 (HLA-AW 68.1, REMARK 900 HUMAN LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 2BNR RELATED DB: PDB REMARK 900 STRUCTURAL AND KINETIC BASIS FOR HIGHTENED IMMUNOGENICITY OF T CELL REMARK 900 VACCINES REMARK 900 RELATED ID: 3HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2. 1 (HLA-A2.1 HUMAN REMARK 900 LEUCOCYTE ANTIGEN) DBREF 2BNQ A 1 276 UNP P01892 1A02_HUMAN 25 300 DBREF 2BNQ B 0 0 PDB 2BNQ 2BNQ 0 0 DBREF 2BNQ B 1 99 UNP P61769 B2MG_HUMAN 21 119 DBREF 2BNQ C 1 9 PDB 2BNQ 2BNQ 1 9 DBREF 2BNQ D 2 204 PDB 2BNQ 2BNQ 2 204 DBREF 2BNQ E 2 112 PDB 2BNQ 2BNQ 2 112 DBREF 2BNQ E 113 242 UNP P01850 TCB_HUMAN 1 130 SEQADV 2BNQ LYS E 116 UNP P01850 ASN 4 CONFLICT SEQADV 2BNQ ASN E 117 UNP P01850 LYS 5 CONFLICT SEQADV 2BNQ TYR E 149 UNP P01850 PHE 37 CONFLICT SEQADV 2BNQ CYS E 169 UNP P01850 SER 57 CONFLICT SEQADV 2BNQ ALA E 187 UNP P01850 CYS 75 CONFLICT SEQADV 2BNQ ASP E 201 UNP P01850 ASN 89 CONFLICT SEQRES 1 A 276 GLY SER HIS SER MET ARG TYR PHE PHE THR SER VAL SER SEQRES 2 A 276 ARG PRO GLY ARG GLY GLU PRO ARG PHE ILE ALA VAL GLY SEQRES 3 A 276 TYR VAL ASP ASP THR GLN PHE VAL ARG PHE ASP SER ASP SEQRES 4 A 276 ALA ALA SER GLN ARG MET GLU PRO ARG ALA PRO TRP ILE SEQRES 5 A 276 GLU GLN GLU GLY PRO GLU TYR TRP ASP GLY GLU THR ARG SEQRES 6 A 276 LYS VAL LYS ALA HIS SER GLN THR HIS ARG VAL ASP LEU SEQRES 7 A 276 GLY THR LEU ARG GLY TYR TYR ASN GLN SER GLU ALA GLY SEQRES 8 A 276 SER HIS THR VAL GLN ARG MET TYR GLY CYS ASP VAL GLY SEQRES 9 A 276 SER ASP TRP ARG PHE LEU ARG GLY TYR HIS GLN TYR ALA SEQRES 10 A 276 TYR ASP GLY LYS ASP TYR ILE ALA LEU LYS GLU ASP LEU SEQRES 11 A 276 ARG SER TRP THR ALA ALA ASP MET ALA ALA GLN THR THR SEQRES 12 A 276 LYS HIS LYS TRP GLU ALA ALA HIS VAL ALA GLU GLN LEU SEQRES 13 A 276 ARG ALA TYR LEU GLU GLY THR CYS VAL GLU TRP LEU ARG SEQRES 14 A 276 ARG TYR LEU GLU ASN GLY LYS GLU THR LEU GLN ARG THR SEQRES 15 A 276 ASP ALA PRO LYS THR HIS MET THR HIS HIS ALA VAL SER SEQRES 16 A 276 ASP HIS GLU ALA THR LEU ARG CYS TRP ALA LEU SER PHE SEQRES 17 A 276 TYR PRO ALA GLU ILE THR LEU THR TRP GLN ARG ASP GLY SEQRES 18 A 276 GLU ASP GLN THR GLN ASP THR GLU LEU VAL GLU THR ARG SEQRES 19 A 276 PRO ALA GLY ASP GLY THR PHE GLN LYS TRP ALA ALA VAL SEQRES 20 A 276 VAL VAL PRO SER GLY GLN GLU GLN ARG TYR THR CYS HIS SEQRES 21 A 276 VAL GLN HIS GLU GLY LEU PRO LYS PRO LEU THR LEU ARG SEQRES 22 A 276 TRP GLU PRO SEQRES 1 B 100 MET ILE GLN ARG THR PRO LYS ILE GLN VAL TYR SER ARG SEQRES 2 B 100 HIS PRO ALA GLU ASN GLY LYS SER ASN PHE LEU ASN CYS SEQRES 3 B 100 TYR VAL SER GLY PHE HIS PRO SER ASP ILE GLU VAL ASP SEQRES 4 B 100 LEU LEU LYS ASN GLY GLU ARG ILE GLU LYS VAL GLU HIS SEQRES 5 B 100 SER ASP LEU SER PHE SER LYS ASP TRP SER PHE TYR LEU SEQRES 6 B 100 LEU TYR TYR THR GLU PHE THR PRO THR GLU LYS ASP GLU SEQRES 7 B 100 TYR ALA CYS ARG VAL ASN HIS VAL THR LEU SER GLN PRO SEQRES 8 B 100 LYS ILE VAL LYS TRP ASP ARG ASP MET SEQRES 1 C 9 SER LEU LEU MET TRP ILE THR GLN VAL SEQRES 1 D 203 GLN GLU VAL THR GLN ILE PRO ALA ALA LEU SER VAL PRO SEQRES 2 D 203 GLU GLY GLU ASN LEU VAL LEU ASN CYS SER PHE THR ASP SEQRES 3 D 203 SER ALA ILE TYR ASN LEU GLN TRP PHE ARG GLN ASP PRO SEQRES 4 D 203 GLY LYS GLY LEU THR SER LEU LEU LEU ILE GLN SER SER SEQRES 5 D 203 GLN ARG GLU GLN THR SER GLY ARG LEU ASN ALA SER LEU SEQRES 6 D 203 ASP LYS SER SER GLY ARG SER THR LEU TYR ILE ALA ALA SEQRES 7 D 203 SER GLN PRO GLY ASP SER ALA THR TYR LEU CYS ALA VAL SEQRES 8 D 203 ARG PRO THR SER GLY GLY SER TYR ILE PRO THR PHE GLY SEQRES 9 D 203 ARG GLY THR SER LEU ILE VAL HIS PRO TYR ILE GLN ASN SEQRES 10 D 203 PRO ASP PRO ALA VAL TYR GLN LEU ARG ASP SER LYS SER SEQRES 11 D 203 SER ASP LYS SER VAL CYS LEU PHE THR ASP PHE ASP SER SEQRES 12 D 203 GLN THR ASN VAL SER GLN SER LYS ASP SER ASP VAL TYR SEQRES 13 D 203 ILE THR ASP LYS CYS VAL LEU ASP MET ARG SER MET ASP SEQRES 14 D 203 PHE LYS SER ASN SER ALA VAL ALA TRP SER ASN LYS SER SEQRES 15 D 203 ASP PHE ALA CYS ALA ASN ALA PHE ASN ASN SER ILE ILE SEQRES 16 D 203 PRO GLU ASP THR PHE PHE PRO SER SEQRES 1 E 241 GLY VAL THR GLN THR PRO LYS PHE GLN VAL LEU LYS THR SEQRES 2 E 241 GLY GLN SER MET THR LEU GLN CYS ALA GLN ASP MET ASN SEQRES 3 E 241 HIS GLU TYR MET SER TRP TYR ARG GLN ASP PRO GLY MET SEQRES 4 E 241 GLY LEU ARG LEU ILE HIS TYR SER VAL GLY ALA GLY ILE SEQRES 5 E 241 THR ASP GLN GLY GLU VAL PRO ASN GLY TYR ASN VAL SER SEQRES 6 E 241 ARG SER THR THR GLU ASP PHE PRO LEU ARG LEU LEU SER SEQRES 7 E 241 ALA ALA PRO SER GLN THR SER VAL TYR PHE CYS ALA SER SEQRES 8 E 241 SER TYR VAL GLY ASN THR GLY GLU LEU PHE PHE GLY GLU SEQRES 9 E 241 GLY SER ARG LEU THR VAL LEU GLU ASP LEU LYS ASN VAL SEQRES 10 E 241 PHE PRO PRO GLU VAL ALA VAL PHE GLU PRO SER GLU ALA SEQRES 11 E 241 GLU ILE SER HIS THR GLN LYS ALA THR LEU VAL CYS LEU SEQRES 12 E 241 ALA THR GLY PHE TYR PRO ASP HIS VAL GLU LEU SER TRP SEQRES 13 E 241 TRP VAL ASN GLY LYS GLU VAL HIS SER GLY VAL CYS THR SEQRES 14 E 241 ASP PRO GLN PRO LEU LYS GLU GLN PRO ALA LEU ASN ASP SEQRES 15 E 241 SER ARG TYR ALA LEU SER SER ARG LEU ARG VAL SER ALA SEQRES 16 E 241 THR PHE TRP GLN ASP PRO ARG ASN HIS PHE ARG CYS GLN SEQRES 17 E 241 VAL GLN PHE TYR GLY LEU SER GLU ASN ASP GLU TRP THR SEQRES 18 E 241 GLN ASP ARG ALA LYS PRO VAL THR GLN ILE VAL SER ALA SEQRES 19 E 241 GLU ALA TRP GLY ARG ALA ASP FORMUL 6 HOH *527(H2 O) HELIX 1 1 ALA A 49 GLU A 53 5 5 HELIX 2 2 GLY A 56 TYR A 85 1 30 HELIX 3 3 ASP A 137 ALA A 150 1 14 HELIX 4 4 HIS A 151 GLY A 162 1 12 HELIX 5 5 GLY A 162 GLY A 175 1 14 HELIX 6 6 GLY A 175 GLN A 180 1 6 HELIX 7 7 GLN A 253 GLN A 255 5 3 HELIX 8 8 GLN D 81 SER D 85 5 5 HELIX 9 9 ARG D 167 ASP D 170 5 4 HELIX 10 10 ALA D 186 PHE D 191 1 6 HELIX 11 11 ALA E 81 THR E 85 5 5 HELIX 12 12 ASP E 114 VAL E 118 5 5 HELIX 13 13 SER E 129 GLN E 137 1 9 HELIX 14 14 ALA E 196 GLN E 200 1 5 SHEET 1 AA 8 GLU A 46 PRO A 47 0 SHEET 2 AA 8 THR A 31 ASP A 37 -1 O ARG A 35 N GLU A 46 SHEET 3 AA 8 ARG A 21 VAL A 28 -1 O ALA A 24 N PHE A 36 SHEET 4 AA 8 HIS A 3 VAL A 12 -1 O ARG A 6 N TYR A 27 SHEET 5 AA 8 THR A 94 VAL A 103 -1 O VAL A 95 N SER A 11 SHEET 6 AA 8 PHE A 109 TYR A 118 -1 N LEU A 110 O ASP A 102 SHEET 7 AA 8 LYS A 121 LEU A 126 -1 O LYS A 121 N TYR A 118 SHEET 8 AA 8 TRP A 133 ALA A 135 -1 O THR A 134 N ALA A 125 SHEET 1 AB 4 LYS A 186 ALA A 193 0 SHEET 2 AB 4 GLU A 198 PHE A 208 -1 O THR A 200 N HIS A 192 SHEET 3 AB 4 PHE A 241 PRO A 250 -1 O PHE A 241 N PHE A 208 SHEET 4 AB 4 GLU A 229 LEU A 230 -1 O GLU A 229 N ALA A 246 SHEET 1 AC 4 LYS A 186 ALA A 193 0 SHEET 2 AC 4 GLU A 198 PHE A 208 -1 O THR A 200 N HIS A 192 SHEET 3 AC 4 PHE A 241 PRO A 250 -1 O PHE A 241 N PHE A 208 SHEET 4 AC 4 ARG A 234 PRO A 235 -1 O ARG A 234 N GLN A 242 SHEET 1 AD 4 GLU A 222 ASP A 223 0 SHEET 2 AD 4 THR A 214 ARG A 219 -1 O ARG A 219 N GLU A 222 SHEET 3 AD 4 TYR A 257 GLN A 262 -1 O THR A 258 N GLN A 218 SHEET 4 AD 4 LEU A 270 ARG A 273 -1 O LEU A 270 N VAL A 261 SHEET 1 BA 4 LYS B 6 SER B 11 0 SHEET 2 BA 4 ASN B 21 PHE B 30 -1 O ASN B 24 N TYR B 10 SHEET 3 BA 4 PHE B 62 PHE B 70 -1 O PHE B 62 N PHE B 30 SHEET 4 BA 4 GLU B 50 HIS B 51 -1 O GLU B 50 N TYR B 67 SHEET 1 BB 4 LYS B 6 SER B 11 0 SHEET 2 BB 4 ASN B 21 PHE B 30 -1 O ASN B 24 N TYR B 10 SHEET 3 BB 4 PHE B 62 PHE B 70 -1 O PHE B 62 N PHE B 30 SHEET 4 BB 4 SER B 55 PHE B 56 -1 O SER B 55 N TYR B 63 SHEET 1 BC 4 GLU B 44 ARG B 45 0 SHEET 2 BC 4 GLU B 36 LYS B 41 -1 O LYS B 41 N GLU B 44 SHEET 3 BC 4 TYR B 78 ASN B 83 -1 O ALA B 79 N LEU B 40 SHEET 4 BC 4 LYS B 91 LYS B 94 -1 O LYS B 91 N VAL B 82 SHEET 1 DA 5 VAL D 4 THR D 5 0 SHEET 2 DA 5 LEU D 19 PHE D 25 -1 O SER D 24 N THR D 5 SHEET 3 DA 5 ARG D 72 ILE D 77 -1 O SER D 73 N CYS D 23 SHEET 4 DA 5 LEU D 62 ASP D 67 -1 O ASN D 63 N TYR D 76 SHEET 5 DA 5 GLU D 56 SER D 59 -1 O GLN D 57 N ALA D 64 SHEET 1 DB 5 ALA D 10 PRO D 14 0 SHEET 2 DB 5 THR D 108 HIS D 113 1 O SER D 109 N LEU D 11 SHEET 3 DB 5 ALA D 86 PRO D 94 -1 O ALA D 86 N LEU D 110 SHEET 4 DB 5 ILE D 30 GLN D 38 -1 N TYR D 31 O ARG D 93 SHEET 5 DB 5 LEU D 44 GLN D 51 -1 O THR D 45 N ARG D 37 SHEET 1 DC 4 ALA D 10 PRO D 14 0 SHEET 2 DC 4 THR D 108 HIS D 113 1 O SER D 109 N LEU D 11 SHEET 3 DC 4 ALA D 86 PRO D 94 -1 O ALA D 86 N LEU D 110 SHEET 4 DC 4 THR D 103 PHE D 104 -1 O THR D 103 N VAL D 92 SHEET 1 DD 7 ALA D 122 ARG D 127 0 SHEET 2 DD 7 SER D 135 THR D 140 -1 O VAL D 136 N LEU D 126 SHEET 3 DD 7 PHE D 171 SER D 180 -1 O ALA D 176 N PHE D 139 SHEET 4 DD 7 VAL D 156 ILE D 158 -1 O TYR D 157 N TRP D 179 SHEET 5 DD 7 PHE D 171 SER D 180 -1 O TRP D 179 N TYR D 157 SHEET 6 DD 7 CYS D 162 MET D 166 -1 O CYS D 162 N SER D 175 SHEET 7 DD 7 PHE D 171 SER D 180 -1 O PHE D 171 N MET D 166 SHEET 1 EA 4 VAL E 3 THR E 6 0 SHEET 2 EA 4 MET E 18 GLN E 24 -1 O GLN E 21 N THR E 6 SHEET 3 EA 4 LEU E 75 LEU E 77 -1 O LEU E 75 N LEU E 20 SHEET 4 EA 4 ASN E 64 VAL E 65 -1 O ASN E 64 N ARG E 76 SHEET 1 EB 9 PHE E 9 LYS E 13 0 SHEET 2 EB 9 SER E 107 LEU E 112 1 O ARG E 108 N GLN E 10 SHEET 3 EB 9 SER E 86 SER E 93 -1 O SER E 86 N LEU E 109 SHEET 4 EB 9 ILE E 53 GLN E 56 0 SHEET 5 EB 9 GLY E 41 GLY E 50 -1 O TYR E 47 N ASP E 55 SHEET 6 EB 9 TYR E 30 ASP E 37 -1 O MET E 31 N SER E 48 SHEET 7 EB 9 SER E 86 SER E 93 -1 O VAL E 87 N GLN E 36 SHEET 8 EB 9 PHE E 102 PHE E 103 -1 O PHE E 102 N SER E 92 SHEET 9 EB 9 SER E 86 SER E 93 -1 O SER E 92 N PHE E 102 SHEET 1 EC 7 GLU E 122 PHE E 126 0 SHEET 2 EC 7 LYS E 138 PHE E 148 -1 O VAL E 142 N PHE E 126 SHEET 3 EC 7 TYR E 186 SER E 195 -1 O TYR E 186 N PHE E 148 SHEET 4 EC 7 VAL E 168 THR E 170 -1 O CYS E 169 N ARG E 191 SHEET 5 EC 7 TYR E 186 SER E 195 -1 O ARG E 191 N CYS E 169 SHEET 6 EC 7 LEU E 175 LYS E 176 -1 O LEU E 175 N ALA E 187 SHEET 7 EC 7 TYR E 186 SER E 195 -1 O ALA E 187 N LEU E 175 SHEET 1 ED 4 LYS E 162 VAL E 164 0 SHEET 2 ED 4 VAL E 153 VAL E 159 -1 O TRP E 157 N VAL E 164 SHEET 3 ED 4 HIS E 205 PHE E 212 -1 O ARG E 207 N TRP E 158 SHEET 4 ED 4 GLN E 231 TRP E 238 -1 O GLN E 231 N PHE E 212 SSBOND 1 CYS A 101 CYS A 164 1555 1555 2.05 SSBOND 2 CYS A 203 CYS A 259 1555 1555 2.03 SSBOND 3 CYS B 25 CYS B 80 1555 1555 2.04 SSBOND 4 CYS D 23 CYS D 90 1555 1555 2.04 SSBOND 5 CYS D 137 CYS D 187 1555 1555 2.04 SSBOND 6 CYS D 162 CYS E 169 1555 1555 2.04 SSBOND 7 CYS E 22 CYS E 90 1555 1555 2.03 SSBOND 8 CYS E 143 CYS E 208 1555 1555 2.03 CISPEP 1 TYR A 209 PRO A 210 0 0.07 CISPEP 2 HIS B 31 PRO B 32 0 0.15 CISPEP 3 ILE D 7 PRO D 8 0 0.00 CISPEP 4 THR E 6 PRO E 7 0 -0.20 CISPEP 5 TYR E 149 PRO E 150 0 0.01 CRYST1 72.563 62.490 116.955 90.00 105.34 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013781 0.000000 0.003780 0.00000 SCALE2 0.000000 0.016003 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008866 0.00000